GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Progenics Pharmaceuticals Inc (NAS:PGNX) » Definitions » ROC %

Progenics Pharmaceuticals (Progenics Pharmaceuticals) ROC % : -100.29% (As of Mar. 2020)


View and export this data going back to 1997. Start your Free Trial

What is Progenics Pharmaceuticals ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Progenics Pharmaceuticals's annualized return on capital (ROC %) for the quarter that ended in Mar. 2020 was -100.29%.

As of today (2024-05-05), Progenics Pharmaceuticals's WACC % is 0.00%. Progenics Pharmaceuticals's ROC % is 0.00% (calculated using TTM income statement data). Progenics Pharmaceuticals earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Progenics Pharmaceuticals ROC % Historical Data

The historical data trend for Progenics Pharmaceuticals's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Progenics Pharmaceuticals ROC % Chart

Progenics Pharmaceuticals Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -86.01 14.66 -88.68 -106.97 -128.85

Progenics Pharmaceuticals Quarterly Data
Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -140.40 -121.30 -123.90 -71.41 -100.29

Progenics Pharmaceuticals ROC % Calculation

Progenics Pharmaceuticals's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2019 is calculated as:

ROC % (A: Dec. 2019 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2018 ) + Invested Capital (A: Dec. 2019 ))/ count )
=-65.243 * ( 1 - -0.02% )/( (37.837 + 63.454)/ 2 )
=-65.2560486/50.6455
=-128.85 %

where

Invested Capital(A: Dec. 2018 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=169.497 - 10.977 - ( 137.686 - max(0, 23.446 - 144.129+137.686))
=37.837

Progenics Pharmaceuticals's annualized Return on Capital (ROC %) for the quarter that ended in Mar. 2020 is calculated as:

ROC % (Q: Mar. 2020 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2019 ) + Invested Capital (Q: Mar. 2020 ))/ count )
=-64.744 * ( 1 - 0% )/( (63.454 + 65.654)/ 2 )
=-64.744/64.554
=-100.29 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2020) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Progenics Pharmaceuticals  (NAS:PGNX) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Progenics Pharmaceuticals's WACC % is 0.00%. Progenics Pharmaceuticals's ROC % is 0.00% (calculated using TTM income statement data). Progenics Pharmaceuticals earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Progenics Pharmaceuticals ROC % Related Terms

Thank you for viewing the detailed overview of Progenics Pharmaceuticals's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Progenics Pharmaceuticals (Progenics Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
One World Trade Center, Suite J, 47th Floor, New York, NY, USA, 10007
Progenics Pharmaceuticals Inc is an oncology company focused on developing and commercializing targeted medicines and artificial intelligence to treat cancer. Its portfolio includes AZEDRA (to treat malignant and recurrent pheochromocytoma and paraganglioma); 1404 and PyL (imaging agents for prostate cancer); 1404 Index and PyL (analytical tools for analysis and indexing of images for prostate cancer); 1095 (treatment of metastatic prostate cancer); PSMA ADC (treatment of metastatic castration-resistant prostate cancer); and EXINI boneBSI (an analytical Bone Scan Index tool from bone scintigraphy images, currently sold in Europe and Japan). Its partnered products are RELISTOR (sold in the U.S., EU, Australia, and Canada) to treat opioid-induced constipation, and the PRO 140 HIV treatment.
Executives
Asha Das officer: Chief Medical Officer C/O PROGENICS PHARMACEUTICALS, INC., 1 WORLD TRADE CENTER, 47TH FL, SUITE J, NEW YORK NY 10007
Ann L. Macdougall director C/O OPIANT PHARMACEUTICALS, INC., 401 WILSHIRE BOULEVARD, 12TH FLOOR, SANTA MONICA CA 90401
Karen Jean Ferrante director 150 ADIRONDACK DRIVE, EAST GREENWICH RI 02818
Heinz Christoph Maeusli director SCHUETZENWEG 3, ENGELBURG V8 9032
Gerard Ber director C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169
Eric J Ende director C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Bradley L Campbell director C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Balaji Venkataraman 10 percent owner, other: See Explanation of Responses FIRST HORIZON PHARMACEUTICAL CORP, 660 HEMBREE PKWY STE 106, ROSWELL GA 30076
Virinder Nohria 10 percent owner, other: See Explanation of Responses 1055 POWERS PLACE, SUITE B, ALPHARETTA GA 30009
Nicole Williams director
David A Scheinberg director 325 CENTRAL PARK W, APT 38, NEW YORK NY 10025
Michael D Kishbauch director 18 CHERRYVILLE RD, FLEMINGTON NJ 08822
Broadfin Healthcare Master Fund Ltd 10 percent owner C/O 20 GENESIS CLOSE, ANSBACHER HOUSE, 2ND FLOOR, PO BOX 1344, GRAND CAYMAN E9 KY1-1108
Kevin Kotler 10 percent owner C/O BROADFIN CAPITAL, LLC, 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Broadfin Capital, Llc 10 percent owner 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022

Progenics Pharmaceuticals (Progenics Pharmaceuticals) Headlines

From GuruFocus

Progenics Sends Letter to Shareholders

By Marketwired Marketwired 10-21-2019

Progenics Sends Letter to Shareholders

By Marketwired Marketwired 10-10-2019